Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190918 · ClinicalTrials.gov registry record · Phase 2
A Trial for Patients With Gestational Trophoblastic Disease
A Phase 2 study of Choriocarcinoma and Uterine Neoplasms, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00190918: Completed Phase 2 study of Choriocarcinoma and Uterine Neoplasms, sponsored by Eli Lilly and Company.
NCT00190918 is a Phase 2 study of Choriocarcinoma and Uterine Neoplasms that has completed, run by Eli Lilly and Company. The registered enrollment target is 50 participants, below the 358-participant average among 5 other Choriocarcinoma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00190918, a Phase 2 study of Choriocarcinoma and Uterine Neoplasms, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II study is evaluating the activity of Pemetrexed in patients diagnosed with low risk Gestational Trophoblastic Tumor (GTT) that have failed prior treatment.
Conditions Studied
Interventions
- DRUG Pemetrexed
Study Locations (1)
Pennsylvania
- Gynecologic Oncology Group 215-854-0770 - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
What the finished NCT00190918 record still lists
NCT00190918 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 358-participant average among 5 other Choriocarcinoma trials with a reported enrollment target (86% lower).
The record links to 4 conditions, with Choriocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Pemetrexed is the first listed.
NCT00190918 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00190918 about?
NCT00190918 is a clinical study titled "A Trial for Patients With Gestational Trophoblastic Disease". This phase II study is evaluating the activity of Pemetrexed in patients diagnosed with low risk Gestational Trophoblastic Tumor (GTT) that have failed prior treatment.
What is the current status of trial NCT00190918?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2006-07. Estimated completion is 2007-07.
What conditions does trial NCT00190918 study?
This clinical trial studies the following conditions: Choriocarcinoma, Uterine Neoplasms, Hydatidiform Mole, Trophoblastic Neoplasms.
What interventions are being tested in trial NCT00190918?
The interventions under investigation include: Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00190918?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00190918 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Choriocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
RECRUITING · Phase 2
-
TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma
COMPLETED · Phase 2
-
Molecular Epidemiology of Pediatric Germ Cell Tumors
RECRUITING
-
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
ACTIVE NOT RECRUITING · Phase 3
-
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia